Cargando…
Mechanism of hepatic targeting via oral administration of DSPE–PEG–cholic acid-modified nanoliposomes
In oral administration, gastrointestinal physiological environment, gastrointestinal epithelial cell membranes, and blood circulation are typical biological barriers to hepatic delivery of ligand-modified nanoparticle drug delivery systems. To elucidate the mechanism of oral hepatic targeting of cho...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339015/ https://www.ncbi.nlm.nih.gov/pubmed/28280334 http://dx.doi.org/10.2147/IJN.S125047 |
_version_ | 1782512604877422592 |
---|---|
author | Li, Ying Zhu, Chunyan |
author_facet | Li, Ying Zhu, Chunyan |
author_sort | Li, Ying |
collection | PubMed |
description | In oral administration, gastrointestinal physiological environment, gastrointestinal epithelial cell membranes, and blood circulation are typical biological barriers to hepatic delivery of ligand-modified nanoparticle drug delivery systems. To elucidate the mechanism of oral hepatic targeting of cholic acid receptor-mediated nanoliposomes (LPs) (distearoyl phosphatidylethanolamine–polyethylene glycol–cholic acid-modified LPs, CA-LPs), evaluations were performed on colon cancer Caco-2 cell monolayers, liver cancer HepG2 cells, and a rat intestinal perfusion model. CA-LPs, ~100 nm in diameter, exhibited sustained-release behavior and had the greatest stability in rat gastrointestinal fluid and serum for both size and entrapment efficiency. CA-LPs demonstrated highest transport across Caco-2 cells and highest cellular uptake by HepG2 cells. The enhanced endocytosis of CA-LPs was found to be mediated by Na(+)/taurocholate cotransporting polypeptide and involved the caveolin-mediated endocytosis pathway. Further, we used fluorescence resonance energy transfer (FRET) technology to show that the CA-LPs maintained their structural integrity in part during the transport across the Caco-2 cell monolayer and uptake by HepG2 cells. |
format | Online Article Text |
id | pubmed-5339015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53390152017-03-09 Mechanism of hepatic targeting via oral administration of DSPE–PEG–cholic acid-modified nanoliposomes Li, Ying Zhu, Chunyan Int J Nanomedicine Original Research In oral administration, gastrointestinal physiological environment, gastrointestinal epithelial cell membranes, and blood circulation are typical biological barriers to hepatic delivery of ligand-modified nanoparticle drug delivery systems. To elucidate the mechanism of oral hepatic targeting of cholic acid receptor-mediated nanoliposomes (LPs) (distearoyl phosphatidylethanolamine–polyethylene glycol–cholic acid-modified LPs, CA-LPs), evaluations were performed on colon cancer Caco-2 cell monolayers, liver cancer HepG2 cells, and a rat intestinal perfusion model. CA-LPs, ~100 nm in diameter, exhibited sustained-release behavior and had the greatest stability in rat gastrointestinal fluid and serum for both size and entrapment efficiency. CA-LPs demonstrated highest transport across Caco-2 cells and highest cellular uptake by HepG2 cells. The enhanced endocytosis of CA-LPs was found to be mediated by Na(+)/taurocholate cotransporting polypeptide and involved the caveolin-mediated endocytosis pathway. Further, we used fluorescence resonance energy transfer (FRET) technology to show that the CA-LPs maintained their structural integrity in part during the transport across the Caco-2 cell monolayer and uptake by HepG2 cells. Dove Medical Press 2017-02-28 /pmc/articles/PMC5339015/ /pubmed/28280334 http://dx.doi.org/10.2147/IJN.S125047 Text en © 2017 Li and Zhu. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Li, Ying Zhu, Chunyan Mechanism of hepatic targeting via oral administration of DSPE–PEG–cholic acid-modified nanoliposomes |
title | Mechanism of hepatic targeting via oral administration of DSPE–PEG–cholic acid-modified nanoliposomes |
title_full | Mechanism of hepatic targeting via oral administration of DSPE–PEG–cholic acid-modified nanoliposomes |
title_fullStr | Mechanism of hepatic targeting via oral administration of DSPE–PEG–cholic acid-modified nanoliposomes |
title_full_unstemmed | Mechanism of hepatic targeting via oral administration of DSPE–PEG–cholic acid-modified nanoliposomes |
title_short | Mechanism of hepatic targeting via oral administration of DSPE–PEG–cholic acid-modified nanoliposomes |
title_sort | mechanism of hepatic targeting via oral administration of dspe–peg–cholic acid-modified nanoliposomes |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339015/ https://www.ncbi.nlm.nih.gov/pubmed/28280334 http://dx.doi.org/10.2147/IJN.S125047 |
work_keys_str_mv | AT liying mechanismofhepatictargetingviaoraladministrationofdspepegcholicacidmodifiednanoliposomes AT zhuchunyan mechanismofhepatictargetingviaoraladministrationofdspepegcholicacidmodifiednanoliposomes |